Kamei J, Morita K, Kashiwazaki T, Ohsawa M
Department of Pathophysiology and Therapeutics, Faculty of Pharmaceutical Sciences, Hoshi University, Tokyo, Japan.
Eur J Pharmacol. 1998 Apr 24;347(2-3):253-5. doi: 10.1016/s0014-2999(98)00176-9.
The effect of moguisteine, a novel peripherally acting non-narcotic antitussive drug, on allergic coughs was examined in guinea pigs. Male Hartley guinea pigs were actively sensitized to ovalbumin. The number of coughs elicited over 5 min following a 2-min exposure to ovalbumin was counted. Exposure of sensitized guinea pigs to 0.5% ovalbumin aerosol induced 22.0 +/- 3.2 coughs/5 min. Moguisteine at doses of 30 and 56 mg/kg, p.o., dose-dependently and significantly suppressed the number of allergic coughs. Dihydrocodeine at doses of 30 and 56 mg/kg, p.o., dose-dependently but not significantly reduced the number of allergic coughs. These results suggest that moguisteine may be of a therapeutic benefit in reducing allergic coughs.
在豚鼠中研究了新型外周作用非麻醉性镇咳药莫吉司坦对过敏性咳嗽的影响。雄性Hartley豚鼠被主动致敏于卵清蛋白。在暴露于卵清蛋白2分钟后,计数5分钟内引发的咳嗽次数。将致敏豚鼠暴露于0.5%卵清蛋白气雾剂中,可诱发22.0±3.2次咳嗽/5分钟。口服剂量为30和56mg/kg的莫吉司坦剂量依赖性且显著抑制过敏性咳嗽次数。口服剂量为30和56mg/kg的二氢可待因剂量依赖性但未显著减少过敏性咳嗽次数。这些结果表明,莫吉司坦在减轻过敏性咳嗽方面可能具有治疗益处。